Fig. 2

BCG-Nanocage promote antibacterial responses of macrophages (MΦ) with reduced cytotoxicity than live BCG bacillus. A Effects of live BCG bacillus and BCG-Nanocage on cell viability of THP-1 macrophages after 3 day treatment determined by MTT assay. B Effects of BCG and BCG-Nanocage on living cell percentages of THP-1 macrophages after 3 day treatment, followed by flow cytometry analysis. C Effects of BCG and BCG-Nanocage on CD14+ macrophages of THP-1 cells after 3 day treatment, followed by flow cytometry analysis. D Typical flow cytometry panel of BCG- or BCG-Nanocage-treated PBMCs from rhesus macaques after 6 day treatments. E Typical flow cytometry panel for the CD206 expression in THP-1 macrophages after 3 days of BCG or BCG-Nanocage treatments. F Effects of BCG and BCG-Nanocage on CD206 expression on macrophages, n = 3, *p < 0.05. G Typical flow cytometry panel for the CD80 expression in THP-1 macrophages after 3 days of BCG or BCG-Nanocage treatments. H Effects of BCG and BCG-Nanocage on CD80 expression on macrophages, n = 3, *p < 0.05, ***p < 0.001. I Typical flow cytometry panel for the IFN-γ expression in THP-1 macrophages after 3 days of BCG or BCG-Nanocage treatments. J Effects of BCG and BCG-Nanocage on IFN-γ+ macroghages, n = 3, ***p < 0.001. K Typical flow cytometry panel for the TNF-α expression in THP-1 macrophages after 3 days of BCG or BCG-Nanocage treatments. L Effects of BCG and BCG-Nanocage on TNF-α expression by macrophages, n = 3, ***p < 0.001